Short-Term Cost-Effectiveness of Glucagon-Like Peptide-1 Receptor Analogues Versus Sodium-Glucose Cotransporter-2 Inhibitors as Second-Line Add-On Therapy for Type 2 Diabetes in the United States
May 1, 2018, 00:00 AM
10.1016/j.jval.2018.04.504
https://www.valueinhealthjournal.com/article/S1098-3015(18)30804-0/fulltext
Section Title :
Section Order :
1308
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30804-0&doi=10.1016/j.jval.2018.04.504